Chitsuthipakorn W.Pooldum V.Phetpong J.Lawpoolsri S.Kanjanawasee D.Kowatanamongkon P.Mongkolkul K.Seresirikachorn K.Snidvongs K.Mahidol University2026-03-292026-03-292026-01-01World Journal of Otorhinolaryngology Head and Neck Surgery (2026)20958811https://repository.li.mahidol.ac.th/handle/123456789/115871Objectives: The Chronic Rhinosinusitis Patient-Reported Outcome (CRS-PRO) questionnaire was recently developed for use in chronic rhinosinusitis (CRS) patients. This instrument was developed using current diagnostic criteria. This study aimed to translate and validate CRS-PRO for Thai CRS patients. Methods: The three-phase translation process and validation were conducted at Rajavithi Hospital, a tertiary hospital in Bangkok, Thailand. Adults (> 18 years) with primary CRS, diagnosed using EPOS2020 criteria, were recruited alongside non-CRS controls. Discriminant validity was assessed by comparing scores between CRS patients and non-CRS controls. Concurrent validity was evaluated by correlating CRS-PRO with the Thai version of the Sinonasal Outcome Test-22 (SNOT-22). Reliability was assessed using internal consistency (Cronbach's alpha) and test–retest reliability using intraclass correlation coefficient (ICC). Results: A total of 85 CRS patients and 40 non-CRS controls were enrolled. The Thai CRS-PRO was completed in (101.80 ± 26.36) seconds. CRS patients had significantly higher scores than controls (16 [10–24] vs. 2 [0–5], p < 0.001) (median [IQR]). CRS-PRO demonstrated strong concurrent validity with SNOT-22 (ρ = 0.82, p < 0.001), high internal consistency (Cronbach's alpha = 0.89), and high test–retest reliability (ICC = 0.81, 95% confidence interval 0.72–0.88). Conclusions: The Thai-translated CRS-PRO has been developed and validated. It demonstrated significant discriminant validity between patients and non-patients, a very strong correlation with the Thai version of SNOT-22, and good reliability. Its brevity and time efficiency support its applicability in both clinical practice and research, enhancing its potential for widespread adoption.MedicineArticleSCOPUS10.1002/wjo2.701012-s2.0-10503305844825891081